Clinical trials

  • PATRITUMAB DERUXTECAN for EGFR mutation–positive advanced non-small cell lung cancer
  • ALLO-QUADCAR01-T for Relapsed or refractory B-cell non-Hodgkin lymphoma | Chronic lymphocytic leukaemia
  • GTAEXS617 for Advanced solid tumours|Non-small cell lung cancer|Ovarian epithelial cancer|Breast cancer|Pancreatic adenocarcinoma|Squamous cell carcinoma of head and neck
  • Talquetamab for Multiple myeloma
  • BEVACIZUMAB for Persistent or recurrent epithelial ovarian cancer | Ovarian epithelial cancer
  • GALLIUM (68GA) CHLORIDE for Inflammatory disorders
  • Roxadustat for Cardiovascular disease risk factors|Metabolic syndrome
  • EFGARTIGIMOD ALFA for Antibody-mediated rejection
  • RMC-6291 for Non-small cell lung cancer | Pancreatic adenocarcinoma | Colorectal cancer
  • Infliximab for Ulcerative colitis | Crohn's disease | Inflammatory bowel disease (IBDU)
  • BALCINRENONE, DAPAGLIFLOZIN for Heart failure | Chronic kidney disease
  • VEDOLIZUMAB for Crohn's disease